Skip to content

Observing the Changes of Endocrine and Metabolism in Patients With Thalassemia Major

Observing the Changes of Endocrine and Metabolism in Patients With Thalassemia Major

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03951818
Enrollment
100
Registered
2019-05-15
Start date
2019-04-01
Completion date
2024-04-01
Last updated
2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia Major

Brief summary

Patient with thalassemia major have many endocrine diseases, such as hypopituitarism, hypothyroidism, hypoparathyroidis, osteoporosis, and etc.. These problems may be due to anemia itself or related to iron deposition. This study aimed to investigate the endocrine aspect of thalassemia major patients in Taiwan in order to introduce early intervention or treatment in the future.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Thalassemia major * Patients of 20-85 years old

Exclusion criteria

* Patients younger than 20 years old. * Patients older than 85 years old. * Patients who are pregnant

Design outcomes

Primary

MeasureTime frameDescription
Abnormal bone mineral density rate10 yearsabnormal bone mineral density is defined as T-score \< -1 SD in menopause women or men older than 50 years old, or Z score \< -2 SD in premenopausal women or men not older than 50 year old.

Secondary

MeasureTime frameDescription
abnormal thyroid function rate10 yearsabnormal thyroid function is defined as abnormal free thyroxine or abnormal thyrotropin. Normal range of free thyroxine is 0.6-1.75 ng/dl. normal range of thyrotropin is 0.1-4.5 mU/l.
abnormal pituitary function rate10 yearsabnormal pituitary function is defined as any of the abnormality in serum adrenocorticotropin (pg/l), IGF-1 (ng/ml). thyrotropin (mU/l), FSH (U/l), LH (U/l)

Countries

Taiwan

Contacts

Primary ContactShyang-Rong Shih, MD, PhD
srshih@ntu.edu.tw+886-972653337

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026